Ascendis Pharma A/S (ASND)
253.38
+1.43
(+0.57%)
USD |
NASDAQ |
Aug 25, 16:00
253.38
0.00 (0.00%)
After-Hours: 16:56
Ascendis Pharma Enterprise Value : 16.13B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 16.13B |
| August 21, 2026 | 16.22B |
| August 20, 2026 | 16.32B |
| August 19, 2026 | 16.64B |
| August 18, 2026 | 15.93B |
| August 17, 2026 | 15.83B |
| August 14, 2026 | 15.91B |
| August 13, 2026 | 15.76B |
| August 12, 2026 | 16.36B |
| August 11, 2026 | 16.30B |
| August 10, 2026 | 16.37B |
| August 07, 2026 | 16.36B |
| August 06, 2026 | 15.99B |
| August 05, 2026 | 15.62B |
| August 04, 2026 | 15.65B |
| August 03, 2026 | 15.57B |
| July 31, 2026 | 15.60B |
| July 30, 2026 | 16.07B |
| July 29, 2026 | 16.14B |
| July 28, 2026 | 16.30B |
| July 27, 2026 | 16.23B |
| July 24, 2026 | 16.26B |
| July 23, 2026 | 16.18B |
| July 22, 2026 | 16.13B |
| July 21, 2026 | 16.35B |
| Date | Value |
|---|---|
| July 20, 2026 | 16.12B |
| July 17, 2026 | 16.73B |
| July 16, 2026 | 16.65B |
| July 15, 2026 | 17.22B |
| July 14, 2026 | 17.03B |
| July 13, 2026 | 17.00B |
| July 10, 2026 | 17.35B |
| July 09, 2026 | 17.67B |
| July 08, 2026 | 17.79B |
| July 07, 2026 | 17.12B |
| July 06, 2026 | 17.18B |
| July 02, 2026 | 17.61B |
| July 01, 2026 | 17.17B |
| June 30, 2026 | 17.10B |
| June 29, 2026 | 16.75B |
| June 26, 2026 | 16.57B |
| June 25, 2026 | 16.62B |
| June 24, 2026 | 15.16B |
| June 23, 2026 | 15.19B |
| June 22, 2026 | 14.53B |
| June 18, 2026 | 14.71B |
| June 17, 2026 | 14.73B |
| June 16, 2026 | 14.73B |
| June 15, 2026 | 14.24B |
| June 12, 2026 | 13.92B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Evaxion AS | 21.46M |
| Genmab A/S | 23.48B |
| Zealand Pharma A/S | 1.219B |
| Cellectis SA | 258.66M |
| BioMarin Pharmaceutical, Inc. | 15.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 240.65M |
| Revenue (Quarterly) | 394.49M |
| Total Expenses (Quarterly) | 153.84M |
| EPS Diluted (Quarterly) | 3.522 |
| Gross Profit Margin (Quarterly) | 90.64% |
| Profit Margin (Quarterly) | 61.00% |
| Earnings Yield | 5.18% |
| Operating Earnings Yield | 0.78% |
| Normalized Earnings Yield | 5.180 |